Emergent BioSolutions Inc. - Product Pipeline Review - 2015
Summary
Global Markets Directs, Emergent BioSolutions Inc. - Product Pipeline Review - 2015, provides an overview of the Emergent BioSolutions Inc.s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Emergent BioSolutions Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Emergent BioSolutions Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Emergent BioSolutions Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Emergent BioSolutions Inc.s pipeline products
Reasons to buy
- Evaluate Emergent BioSolutions Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Emergent BioSolutions Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Emergent BioSolutions Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Emergent BioSolutions Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Emergent BioSolutions Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Emergent BioSolutions Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Emergent BioSolutions Inc. Snapshot 6
Emergent BioSolutions Inc. Overview 6
Key Information 6
Key Facts 6
Emergent BioSolutions Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Emergent BioSolutions Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Emergent BioSolutions Inc. - Pipeline Products Glance 14
Emergent BioSolutions Inc. - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Emergent BioSolutions Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Emergent BioSolutions Inc. - Drug Profiles 19
coagulation factor IX (recombinant) 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
AV-7909 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
otlertuzumab 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
PreviThrax 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
AVP-21D9 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
ES-414 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
antihemophilic factor (recombinant) 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ES-210 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
ES-301 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
ES-306 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
EV-035 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
GC-072 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
MVA-RSV 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
MVAH-5HA 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Recombinant Protein Cytotoxic to Cells Expressing CD19 and CD3 for Cancer 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Recombinant Protein to Target HER-2 and CD3 for Cancer 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Recombinant Protein to Target RON and CD3 for Cancer 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Vaccines for Undisclosed Indication 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Emergent BioSolutions Inc. - Pipeline Analysis 42
Emergent BioSolutions Inc. - Pipeline Products by Target 42
Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 44
Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 45
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 46
Emergent BioSolutions Inc. - Recent Pipeline Updates 48
Emergent BioSolutions Inc. - Dormant Projects 56
Emergent BioSolutions Inc. - Discontinued Pipeline Products 57
Discontinued Pipeline Product Profiles 57
Anthrivig 57
Immune Globulin 57
Leucotropin 57
PEP-35 57
TST-10088 57
Emergent BioSolutions Inc. - Company Statement 58
Emergent BioSolutions Inc. - Locations And Subsidiaries 61
Head Office 61
Other Locations and Subsidiaries 61
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65
List Of Tables
Emergent BioSolutions Inc., Key Information 6
Emergent BioSolutions Inc., Key Facts 6
Emergent BioSolutions Inc. - Pipeline by Indication, 2015 8
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2015 10
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2015 11
Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2015 12
Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2015 13
Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2015 14
Emergent BioSolutions Inc. - Phase II, 2015 15
Emergent BioSolutions Inc. - Phase I, 2015 16
Emergent BioSolutions Inc. - Preclinical, 2015 17
Emergent BioSolutions Inc. - Discovery, 2015 18
Emergent BioSolutions Inc. - Pipeline by Target, 2015 43
Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2015 44
Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2015 45
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2015 47
Emergent BioSolutions Inc. - Recent Pipeline Updates, 2015 48
Emergent BioSolutions Inc. - Dormant Developmental Projects,2015 56
Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2015 57
Emergent BioSolutions Inc., Other Locations 61
Emergent BioSolutions Inc., Subsidiaries 61
List Of Figures
Emergent BioSolutions Inc. - Pipeline by Top 10 Indication, 2015 8
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2015 10
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2015 11
Emergent BioSolutions Inc. - Pipeline by Top 10 Target, 2015 42
Emergent BioSolutions Inc. - Pipeline by Top 10 Route of Administration, 2015 44
Emergent BioSolutions Inc. - Pipeline by Top 10 Molecule Type, 2015 45
Emergent BioSolutions Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 46
